Your browser doesn't support javascript.
loading
Perioperative therapeutic plasma exchange in a patient with rare Factor XIII inhibitor.
Smith, Joshua; Bodine, Jared S; Cunningham, Mark T; Gooley, Kathleen; Plapp, Frederick V; Dasgupta, Amitava; Ye, Zhan.
Afiliación
  • Smith J; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
  • Bodine JS; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
  • Cunningham MT; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
  • Gooley K; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
  • Plapp FV; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
  • Dasgupta A; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
  • Ye Z; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States. Electronic address: zye2@kumc.edu.
Transfus Apher Sci ; 62(3): 103654, 2023 Jun.
Article en En | MEDLINE | ID: mdl-36775674
ABSTRACT

INTRODUCTION:

Factor XIII deficiency is a rare bleeding disorder which could be severe if inherited or less severe if acquired. We report a case of acquired Factor XIII inhibitor in a 75-year-old male with a suspicious left renal mass treated perioperatively with therapeutic plasma exchange (TPE). PATIENT AND

METHOD:

To perform kidney biopsy and ablation of the renal mass, six daily TPE treatments were performed before and after biopsy to minimize bleeding risk because the patient did not respond to drug therapy. Both thromboelastography (TEG) and laboratory-based coagulation tests were performed to assess coagulation status prior to and after TPE.

RESULTS:

The biopsy indicated oncocytoma which was removed by surgical procedure. Factor XIII activity remained below 15 % throughout TPE treatments, but Factor XIII inhibitor titer reduced from initial positive value of 140 to negative following the third TPE and remained negative through the sixth TPE. Unfortunately, the inhibitor titer was positive at 120 in the fifth month and 15 in the sixth month during follow-up.

CONCLUSIONS:

TPE is useful in removing XIII inhibitory factor, but the effects are only short term.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Deficiencia del Factor XIII / Trastornos Hemorrágicos Límite: Aged / Humans / Male Idioma: En Revista: Transfus Apher Sci Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Deficiencia del Factor XIII / Trastornos Hemorrágicos Límite: Aged / Humans / Male Idioma: En Revista: Transfus Apher Sci Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos